Jacobi Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Jacobi Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-690	Closed	-$64K	–	1204
2021 Q3	$64K	Buy	690 +60	+10%	+$4.62K	0.01%	603
2021 Q2	$49K	Sell	630 -150	-19%	-$11.4K	0.01%	630
2021 Q1	$58K	Buy	780 +274	+54%	+$25.3K	0.01%	548
2020 Q4	$86K	Hold	506	–	–	0.01%	436
2020 Q3	$71K	Sell	506 -200	-28%	-$30.4K	0.01%	435
2020 Q2	$113K	Hold	706	–	–	0.02%	352
2020 Q1	$69K	Buy	706 +6	+0.9%	+$686	0.01%	375
2019 Q4	$90K	Buy	700 +500	+250%	+$50.5K	0.02%	366
2019 Q3	$15K	Hold	200	–	–	﹤0.01%	666
2019 Q2	$30K	Hold	200	–	–	0.01%	531
2019 Q1	$24K	Hold	200	–	–	0.01%	540
2018 Q4	$22K	Sell	200 -300	-60%	-$37.5K	0.01%	518
2018 Q3	$81K	Hold	500	–	–	0.02%	356
2018 Q2	$66K	Buy	+500	New	+$47.2K	0.02%	376
2016 Q4	–	Sell	-300	Closed	-$18K	–	690
2016 Q3	$18K	Buy	+300	New	+$9.07K	0.01%	379

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Jacobi Capital Management's SRPT Position: Q4 2021 in Review

Jacobi Capital Management sold out of Sarepta Therapeutics (SRPT) in Q4 2021, closing a stake of 690 shares — an estimated $64K sold.

Jacobi Capital Management first reported a position in SRPT in Q3 2016 and held it in 15 quarters. The position peaked at $113K in Q2 2020. 343 funds tracked by Wall St. Rank hold SRPT as of Q4 2021.

Jacobi Capital Management reported no remaining Sarepta Therapeutics position as of Q4 2021 after selling out during the quarter.
Jacobi Capital Management sold 690 Sarepta Therapeutics shares in Q4 2021, an estimated $64K.
Jacobi Capital Management first reported a position in Sarepta Therapeutics in Q3 2016 and held it in 15 quarters.
Jacobi Capital Management's Sarepta Therapeutics position peaked at $113K in Q2 2020.
343 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2021.

Based on Jacobi Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.